Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Gastrointestinal cancer. Over the RAINBOW--renaissance in antiangiogenesis.

Literature DB >> 25403941

Gastrointestinal cancer. Over the RAINBOW--renaissance in antiangiogenesis.

Abstract

The RAINBOW study has demonstrated that ramucirumab plus paclitaxel as second-line treatment for advanced-stage gastric cancer prolongs survival compared with paclitaxel alone. These data confirm that ramucirumab represents a new effective treatment option for gastric cancer. Nevertheless, new treatment options remain eagerly awaited in this disease with dismal outcomes.

Entities: Chemical Disease

Mesh：

Year: 2014 PMID： 25403941 DOI： 10.1038/nrclinonc.2014.195

Source DB: PubMed Journal: Nat Rev Clin Oncol ISSN： 1759-4774 Impact factor: 66.675

9 in total

1. Gastrointestinal cancer: Salvage chemotherapy in gastric cancer--more than a straw?

Authors: Florian Lordick
Journal: Nat Rev Clin Oncol Date: 2012-05-01 Impact factor: 66.675

Review 2. Unmet needs and challenges in gastric cancer: the way forward.

Authors: Florian Lordick; William Allum; Fátima Carneiro; Emmanuel Mitry; Josep Tabernero; Patrick Tan; Eric Van Cutsem; Cornelis van de Velde; Andrés Cervantes
Journal: Cancer Treat Rev Date: 2014-03-13 Impact factor: 12.111

3. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.

Authors: Atsushi Ohtsu; Manish A Shah; Eric Van Cutsem; Sun Young Rha; Akira Sawaki; Sook Ryun Park; Ho Yeong Lim; Yasuhide Yamada; Jian Wu; Bernd Langer; Michal Starnawski; Yoon-Koo Kang
Journal: J Clin Oncol Date: 2011-08-15 Impact factor: 44.544

4. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.

Authors: Charles S Fuchs; Jiri Tomasek; Cho Jae Yong; Filip Dumitru; Rodolfo Passalacqua; Chanchal Goswami; Howard Safran; Lucas Vieira Dos Santos; Giuseppe Aprile; David R Ferry; Bohuslav Melichar; Mustapha Tehfe; Eldar Topuzov; John Raymond Zalcberg; Ian Chau; William Campbell; Choondal Sivanandan; Joanna Pikiel; Minori Koshiji; Yanzhi Hsu; Astra M Liepa; Ling Gao; Jonathan D Schwartz; Josep Tabernero
Journal: Lancet Date: 2013-10-03 Impact factor: 79.321

5. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial.

Authors: Jin Li; Shukui Qin; Jianming Xu; Weijian Guo; Jianping Xiong; Yuxian Bai; Guoping Sun; Yan Yang; Liwei Wang; Nong Xu; Ying Cheng; Zhehai Wang; Leizhen Zheng; Min Tao; Xiaodong Zhu; Dongmei Ji; Xin Liu; Hao Yu
Journal: J Clin Oncol Date: 2013-08-05 Impact factor: 44.544

6. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.

Authors: Hansjochen Wilke; Kei Muro; Eric Van Cutsem; Sang-Cheul Oh; György Bodoky; Yasuhiro Shimada; Shuichi Hironaka; Naotoshi Sugimoto; Oleg Lipatov; Tae-You Kim; David Cunningham; Philippe Rougier; Yoshito Komatsu; Jaffer Ajani; Michael Emig; Roberto Carlesi; David Ferry; Kumari Chandrawansa; Jonathan D Schwartz; Atsushi Ohtsu
Journal: Lancet Oncol Date: 2014-09-17 Impact factor: 41.316

7. Clinicopathological significance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptor-β phosphorylation, and microvessel density in gastric cancer.

Authors: Shioto Suzuki; Yoh Dobashi; Yayoi Hatakeyama; Ryosuke Tajiri; Takashi Fujimura; Carl H Heldin; Akishi Ooi
Journal: BMC Cancer Date: 2010-11-30 Impact factor: 4.430

8. Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report.

Authors: A F C Okines; R E Langley; L C Thompson; S P Stenning; L Stevenson; S Falk; M Seymour; F Coxon; G W Middleton; D Smith; L Evans; S Slater; J Waters; D Ford; M Hall; T J Iveson; R D Petty; C Plummer; W H Allum; J M Blazeby; M Griffin; D Cunningham
Journal: Ann Oncol Date: 2012-10-28 Impact factor: 32.976

9. Comprehensive molecular characterization of gastric adenocarcinoma.

Authors:
Journal: Nature Date: 2014-07-23 Impact factor: 49.962